Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaxis gets Korean approval for asthma drug
Approval by the Korean regulatory agency was based on the Australian approval and was completed efficiently in just six months. The approval process is expected to conclude in
Approval by the Korean regulatory agency was based on the Australian approval and was completed efficiently in just six months. The approval process is expected to conclude in
The initial product to be jointly promoted in the US is Teva’s ProAirHFA (albuterol sulfate) inhalation aerosol. Additionally, the agreement will provide UCB future joint promotion opportunities with
Kentera was approved through the centralized procedure by the EMEA in 2004 and has been on the market in a number of countries with current sales of over
The lawsuits allege that CryoCath’s products infringe several patents related to CryoCor’s Cardiac Cryoablation System. CryoCor is an exclusive licensee of the patents, and is seeking monetary damages
According to the company, the Arachnova patent rights, which include granted patents and pending applications related to the use of DDP225 for the treatment of functional bowel disorders,
Pro-Stat has been shown to be an effective nutritional intervention to aid in the treatment of pressure ulcers, protein energy malnutrition, recent weight loss, hypoalbuminemia, and end stage
The trial was designed to assess the effects of PRX-03140 following two weeks of treatment as monotherapy and separately in combination with donepezil in patients with mild Alzheimer’s
The filing for Keppra is supported by a Phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of extended-release levetiracetam tablets (2x500mg) once-daily as
This multi-center Phase III trial will include a randomized, double blind, placebo-controlled component to evaluate the efficacy and safety of MAP0004 in treating a single acute attack of
Approval from the FDA to proceed with the pivotal phase of the study is based on the review of an initial feasibility segment completed in August 2007. The